Veraxa Biotech AG - Post de-SPAC(VRXA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
VRXA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Veraxa Biotech AG - Post de-SPAC (VRXA), a Healthcare sector company. VRXA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of VRXA by reported 13-F value include UBS Group AG, GEODE CAPITAL MANAGEMENT, CSS, based on the most recent SEC filings. VRXA trades on the Nasdaq exchange and files with the SEC under CIK 2079109. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRXA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Veraxa Biotech AG - Post de-SPAC directly from SEC EDGAR.
Get alerted when VRXA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Veraxa Biotech AG - Post de-SPAC including:
Top Institutional Holders of VRXA
UBS Group AG
$295.6K157,237 shGEODE CAPITAL MANAGEMENT, LLC
$225.2K119,767 shCSS LLC/IL
$176.6K1,600,882 shLMR Partners LLP
$120.1K1,089,100 shMagnetar Financial LLC
$116.4K1,055,078 shARISTEIA CAPITAL, L.L.C.
$115.7K976,083 shAlberta Investment Management Corp
$96.5K875,000 shAQR Arbitrage LLC
$72.6K658,138 shClear Street Group Inc.
$53.5K485,358 shJPMORGAN CHASE & CO
$43.8K350,256 sh
| Fund | Value | Shares |
|---|---|---|
| UBS Group AG | $295.6K | 157,237 |
| GEODE CAPITAL MANAGEMENT, LLC | $225.2K | 119,767 |
| CSS LLC/IL | $176.6K | 1,600,882 |
| LMR Partners LLP | $120.1K | 1,089,100 |
| Magnetar Financial LLC | $116.4K | 1,055,078 |
| ARISTEIA CAPITAL, L.L.C. | $115.7K | 976,083 |
| Alberta Investment Management Corp | $96.5K | 875,000 |
| AQR Arbitrage LLC | $72.6K | 658,138 |
| Clear Street Group Inc. | $53.5K | 485,358 |
| JPMORGAN CHASE & CO | $43.8K | 350,256 |
More Healthcare Companies
View all Healthcare →Put VRXA on your watchlist
Track score changes the day Veraxa Biotech AG - Post de-SPAC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VRXA a good stock to buy?
13F Pro's AI-powered analysis of Veraxa Biotech AG - Post de-SPAC (VRXA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VRXA are available on the VRXA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VRXA is classified as a small company.
Which hedge funds own VRXA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VRXA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Veraxa Biotech AG - Post de-SPAC's investment landscape.